Clovis Oncology (CLVS) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Clovis Oncology Announces Third Quarter 2018 Operating Results
October 30, 2018 4:05 PM EDT$22.8M in Rubraca® sales for the third quarter of 2018 compared to $16.8M for Q3 2017 Free drug increased to 30 percent of overall commercial supply, equivalent to $9.6 million in commercial value Initial TRITON2 data for Rubraca in mCRPC presented at ESMO include 44% confirmed ORR and 51% confirmed PSA response rate in 25 RECIST-evaluable and 45 PSA-evaluable patients with a BRCA1/2 alteration; preliminary safety data are consistent with those observed in other Rubraca studies $604.4 million in cash, cash equivalents and available for sale securities at September 30, 2018... More
